@article {Vihta2020.10.12.20211243, author = {Karina-Doris Vihta and Nicola Claire Gordon and Nicole Stoesser and T. Phuong Quan and Carina SB Tyrrell and Manivanh Vongsouvath and Elizabeth A Ashley and Vilada Chansamouth and Paul Turner and Clare L Ling and David Eyre and Nicholas J White and Derrick Crook and Tim Peto and Ann Sarah Walker}, title = {Antimicrobial resistance surveillance: can we estimate resistance in bloodstream infections from other types of specimen?}, elocation-id = {2020.10.12.20211243}, year = {2020}, doi = {10.1101/2020.10.12.20211243}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Antimicrobial resistance (AMR) surveillance of bloodstream infections is challenging in low- and middle-income countries (LMICs), limited laboratory capacity preventing routine patient-level susceptibility testing. Other specimen types could provide an effective approach to surveillance.Objectives Our study aims to systematically evaluate the relationship between resistance prevalence in non-sterile sites and bloodstream infections.Methods Associations between resistance rates in Escherichia coli and Staphylococcus aureus isolates from blood and other specimens were estimated in Oxfordshire, UK, 1998-2018, comparing proportions resistant in each calendar year using time series cross-correlations and across drug-years. We repeated analysis across publicly-available data from four high-income and 12 middle-income countries, and in three hospitals/programmes in LMICs.Results 8102 E. coli bloodstream infections, 322087 E. coli urinary tract infections, 6952 S. aureus bloodstream infections and 112074 S. aureus non-sterile site cultures were included from Oxfordshire. Resistance trends over time in blood versus other specimens were strongly correlated (maximum cross-correlation 0.51-0.99, strongest associations in the same year for 18/27 pathogen-drug combinations). Resistance prevalence was broadly congruent across drug-years for each species. 276/312 (88\%) species-drug-years had resistance prevalence in other specimen types within {\textpm}10\% of that blood isolates. Results were similar across multiple countries and hospitals/programmes in high/middle/low income-settings.Conclusions Resistance in bloodstream and less invasive infections are strongly related over time, suggesting the latter could be a surveillance tool for AMR in LMICs. These infection sites are easier to sample and cheaper to obtain the necessary numbers of susceptibility tests, providing more cost-effective evidence for decisions including empiric antibiotic recommendations.Competing Interest StatementTPQ reports grants from National Institute for Health Research, during the conduct of the study; TEAP reports grants from National Institute of Health Research, grants from Wellcome Trust, grants from BBRC, grants from MRC, during the conduct of the study; DWE reports personal fees from Gilead, outside the submitted work. All other authors report no competing interests.Funding StatementThis study was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE) (grant HPRU-2012-10041) and the Oxford NIHR Biomedical Research Centre. ASW is an NIHR Senior Investigator.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IORD: Research Ethics Committee and Confidentiality Advisory Group approval (19/SC/0403, 19/CAG/0144) as a de-identified electronic research databaseAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOxfordshire data comes from the Infections in Oxfordshire Research Database https://oxfordbrc.nihr.ac.uk/research-themes-overview/antimicrobial-resistance-and-modernising-microbiology/infections-in-oxfordshire-research-database-iord/, the ATLAS dataset is publicly available here: https://www.synapse.org/$\#$!Synapse:syn17009517/wiki/585653 The data from Cambodia, Laos and Thailand is not publicly available. https://www.synapse.org/$\#$!Synapse:syn17009517/wiki/585653}, URL = {https://www.medrxiv.org/content/early/2020/10/14/2020.10.12.20211243}, eprint = {https://www.medrxiv.org/content/early/2020/10/14/2020.10.12.20211243.full.pdf}, journal = {medRxiv} }